HALOZYME THERAPEUTICS, INC. (HALO) Operating cash flow 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$651.6MFY2025 · since FY2016: -$50.4M → $651.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $651.6M | +36.0% |
| FY2024 | $479.1M | +23.3% |
| FY2023 | $388.6M | +61.8% |
| FY2022 | $240.1M | -19.8% |
| FY2021 | $299.4M | +440.0% |
| FY2020 | $55.5M | +164.9% |
| FY2019 | -$85.4M | -72.6% |
| FY2018 | -$49.5M | -136.9% |
| FY2017 | $134.1M | +366.1% |
| FY2016 | -$50.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Gross marginHALO Operating incomeHALO Operating marginHALO Free cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →